Description:
Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepressant agent. It was just planed a phase III trial for Major depressive disorder.
- Molecular Weight: 413.47
- Molecular Formula: C18H31N5O6
Purity: ≥98% by HPLC
Canonical SMILES:
CC(C(C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)N)N)O
InChI:
InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
InChIKey: GIBQQARAXHVEGD-BSOLPCOYSA-N
- Boiling Point: 844.2±65.0°C(Predicted)
- Solubility: Soluble in DMF (25 mg/ml), DMSO (15 mg/ml), Ethanol (10 mg/ml)
- Appearance: White to Tan Powder
- Application: Rapastinel is a brain penetrable tetrapeptide and could be a partial agonist of NMDA receptor.
- Storage: Store at -20°C
Synonyms:
GLYX-13; GLYX 13; GLYX13; BV-102; BV102; BV 102; TPPT-amide; Rapastinel; UNII-6A1X56B95E; GLYX-13 trifluoroacetate; TPPT-amide trifluoroacetate
More details are to be found on supplier website
